Merrill Lynch Upgrades Pfizer (PFE) to Buy
More News related to PFE
- Cramer Says Pfizer (PFE) Should Buy Allergan (AGN)
- Pfizer (PFE) Announces Results of Lipitor Study
- Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows
- Pfizer's Novel HIV/AIDS Treatment SELZENTRY(TM) Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients
- Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
More News related to Upgrades
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
Merrill Lynch upgrades Pfizer (NYSE: PFE) from Underperform to Buy, citing the company's dividend yield and business.
Pfizer's dividend yield is currently 6.8%.
Pfizer, Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
Related Categories
UpgradesStocks Mentioned
+0.60Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
